Oscar Murphy, a 28-year-old from Bury, England, recently made headlines as the first patient to receive CAR-T therapy on the NHS for his aggressive form of leukaemia. He described the experience as “fantastic” and even “very sci-fi.”
CAR-T, short for Chimeric Antigen Receptor T-cell therapy, is a groundbreaking immunotherapy that uses modified immune cells to fight cancer. Oscar received his treatment at Manchester Royal Infirmary, where his own T-cells were taken, engineered to target cancer cells, and then infused back into his body.
This innovative treatment is paving the way for change in cancer care. According to recent studies, around 77% of patients in similar trials achieved remission, with about 50% still cancer-free after three and a half years. The average gain in survival was about 15.6 months.
Oscar was diagnosed with B-cell acute lymphoblastic leukaemia in March 2025. After chemotherapy and a stem cell transplant failed, the cancer returned by November. “It needs an even quicker response to stop it. And we’ve now got an answer for that,” he said.
Dr. Eleni Tholouli, Oscar’s haematologist, noted that this therapy is safer and has fewer side effects compared to traditional treatments. “Usually, this type of leukaemia is aggressive and patients don’t live beyond six to eight months. With this therapy, we are able to offer years and possibly a cure.”
The NHS has begun funding this treatment at several locations across England, expected to benefit around 50 patients annually, though some experts predict that number could grow. Prof. Peter Johnson, NHS National Clinical Director for Cancer, called it a “landmark moment” for patients like Oscar.
The treatment involves extracting T-cells, modifying them in a lab, and then reintroducing them into the patient’s bloodstream. Oscar received two infusions that amounted to millions of engineered T-cells, effectively packed in a small vial.
Social media reactions have been overwhelmingly positive, with many celebrating this significant step in cancer treatment and sharing personal stories of hope. Oscar’s journey has inspired others facing similar battles; Chris Williams, who underwent CAR-T therapy during its experimental phase, has been in remission for nearly three years and is now living a fulfilling life.
As Oscar said, “I want children and a normal life,” emphasizing the hope this groundbreaking therapy brings for patients seeking a brighter future. This treatment represents a shift in how we approach aggressive cancers, highlighting the potential for long-term survival and improved quality of life.
For more detailed insights into CAR-T therapy, you can read further at the New England Journal of Medicine.
